

Message

---

**From:** Keigwin, Richard [Keigwin.Richard@epa.gov]  
**Sent:** 5/12/2017 10:28:03 AM  
**To:** Beck, Nancy [Beck.Nancy@epa.gov]; Jakob, Avivah [Jakob.Avivah@epa.gov]  
**CC:** Wise, Louise [Wise.Louise@epa.gov]; Cleland-Hamnett, Wendy [Cleland-Hamnett.Wendy@epa.gov]  
**Subject:** RE: GM mosquitos  
**Attachments:** Oxitec Summary Paper (005) 4-6-17 .docx

Here's a background paper that we prepared a few weeks ago in response to some questions from Senator Inhofe's staff. It's what I have readily available; if you would like to get a deeper dive, we can get you something the early part of next week.

---

**From:** Beck, Nancy  
**Sent:** Thursday, May 11, 2017 7:43 PM  
**To:** Keigwin, Richard <Keigwin.Richard@epa.gov>; Jakob, Avivah <Jakob.Avivah@epa.gov>  
**Cc:** Wise, Louise <Wise.Louise@epa.gov>; Cleland-Hamnett, Wendy <Cleland-Hamnett.Wendy@epa.gov>  
**Subject:** GM mosquitos

Today the Deputy Chief of Staff (aka Byron Brown) met with the chairman and VP of Intrexon (business cards attached). They are very interested in transferring jurisdiction from FDA to EPA and Byron suggested I meet with them. Before I set that up, it would be helpful to get a backgrounder on the coordinated framework and our authorities vs FDA's and what the switch would mean for us.

Might you have something that could help me here?

Thanks!  
Nancy

\*\*\*\*\*

Nancy B. Beck, Ph.D., DABT  
Deputy Assistant Administrator  
Office of Chemical Safety and Pollution Prevention  
P: 202-564-1273  
M: 202-731-9910  
[beck.nancy@epa.gov](mailto:beck.nancy@epa.gov)